NCT02751645

Brief Summary

The investigators primary objective is to determine if acute normovolemic hemodilution (ANH) for pediatric cardiac surgical patients decreases the volume of blood products transfused during surgery and the immediate post-operative period as compared to usual care. This study will enroll 24 pediatric heart surgery patients, aged 6 months to 3 years old undergoing either ANH prior to initiating cardiopulmonary bypass or the standard of care procedures for the use of cardiopulmonary bypass.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 13, 2016

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 26, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

June 30, 2016

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2020

Completed
Last Updated

May 16, 2019

Status Verified

May 1, 2019

Enrollment Period

3.5 years

First QC Date

April 13, 2016

Last Update Submit

May 14, 2019

Conditions

Keywords

PediatricCardiacSurgery

Outcome Measures

Primary Outcomes (1)

  • Effectiveness of ANH to decrease volume of blood products during surgery and the immediate post-operative period.

    This will be measured by comparing the volume (mL/Kg body weight) of any blood products administered peri-operatively between the two groups.

    2 Days

Secondary Outcomes (8)

  • Kidney function

    2 days

  • Normalization of thromboelastogrpahy (TEG) MA value (maximum amplitude)

    2 days

  • Normalization of thromboelastography (TEG) R value (reaction time)

    2 days

  • Normalization of thromboelastography (TEG) Alpha Angle value

    2 days

  • Final hematocrit, platelet count, PT/PTT on ICU admission

    1 day

  • +3 more secondary outcomes

Study Arms (2)

Standard of Care Control

NO INTERVENTION

This group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.

Acute Normovolemic Hemodilution

EXPERIMENTAL

This group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.

Procedure: Acute Normovolemic hemodilution

Interventions

ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.

Acute Normovolemic Hemodilution

Eligibility Criteria

Age6 Months - 3 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Informed signed consent must be obtained by a legally authorized representative.
  • Must be undergoing an elective surgical repair or palliation of a cardiac defect with the use of the cardiopulmonary bypass machine.
  • Must be clinically stable at the time of evaluation for eligibility and on the day of randomization.

You may not qualify if:

  • Patients who carry a diagnosis of a bleeding disorder.
  • Patients who have an abnormal coagulation profile as evidenced by a preoperative coagulation screen.
  • Patients who have received a blood transfusion in the preceding 120 days.
  • Patients who have a diagnosis of a chromosomal abnormality.
  • Patients whose participation in the study is deemed unsafe by their primary care team.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oregon Health and Science University

Portland, Oregon, 97239, United States

Location

Study Officials

  • Miriam Treggiari, MD

    Oregon Health and Science University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 13, 2016

First Posted

April 26, 2016

Study Start

June 30, 2016

Primary Completion

December 31, 2019

Study Completion

May 31, 2020

Last Updated

May 16, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

There are no plans to share the data collected during this study.

Locations